Clinical Trial Update: A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial update reports results for apalutamide (ARN-509) in men with non-metastatic castration-resistant prostate cancer; results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-metastatic Castration-resistant Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)

Snippet

Sponsor: Aragon Pharmaceuticals, Inc. | Conditions: Prostatic Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2018-06-19